A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1044-1051

  Wagner, Andrew J ^a   Messersmith, Wells A ^b   Shaik, M Naveed ^c   Li, Sherry ^c   Zheng, Xianxian ^c   McLachlan, Karen R ^c   Cesari, Rossano ^c   Courtney, Rachel ^c   Levin, Wendy J ^c   El Khoueiry, Anthony B ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GLASDEGIB; TRANSCRIPTION FACTOR GLI1; 1-(2-(1H-BENZO(D)IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; GLI PROTEIN; ONCOPROTEIN; SONIC HEDGEHOG PROTEIN; TRANSACTIVATOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; CANCER CONTROL; CHONDROSARCOMA; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DERMATOFIBROMA; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FAINTNESS; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION REGULATION; GLI1 GENE; HEADACHE; HEART PALPITATION; HUMAN; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC MELANOMA; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRESYNCOPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TONGUE CANCER; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; GENE EXPRESSION; GENETICS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; FEMALE; GENE EXPRESSION; HEDGEHOG PROTEINS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; ONCOGENE PROTEINS; PHENYLUREA COMPOUNDS; TRANS-ACTIVATORS; TREATMENT OUTCOME;

EID: 84929458903     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1116     Document Type: Article

References (31)

1. Ingham PW Hedgehog signaling: a tale of two lipids. Science 2001; 294: 1879-81.
2. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001; 15: 3059-87.
3. Thomas BJ Cell-cycle control during development: taking it up a notch. Dev Cell 2005; 8: 451-2.
4. Straface G, Aprahamian T, Flex A, Gaetani E, Biscetti F, Smith RC, et al. Sonic hedgehog regulates angiogenesis and myogenesis during post-natal skeletal muscle regeneration. J Cell Mol Med 2009; 13: 2424-35.
5. Lin TL, Matsui W. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther 2012; 5: 47-58.
6. Scales SJ, de Sauvage FJ Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009; 30: 303-12.
7. Rubin LL, de Sauvage FJ Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006; 5: 1026-33.
8. Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009; 9: 873-86.
9. Reifenberger J, Wolter M, Knobbe CB, Köhler B, Schönicke A, Scharwächter C, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005; 152: 43-51.
10. Xie J, Johnson RL, Zhang X, Bare JW, Waldman FM, Cogen PH, et al. Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 1997; 57: 2369-72.
11. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007; 13: 944-51.
12. Gialmanidis IP, Bravou V, Amanetopoulou SG, Varakis J, Kourea H, Papadaki H. Overexpression of hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas. Lung Cancer 2009; 66: 64-74.
13. Cheng WT, Xu K, Tian DY, Zhang ZG, Liu LJ, Chen Y. Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells. Int J Oncol 2009; 34: 829-36.
14. Bailey JM, Mohr AM, Hollingsworth MA. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene 2009; 28: 3513-25.
15. Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med 2009; 361: 2094-6.
16. Tian H, Callahan CA, DuPree KJ, Darbonne WC, Ahn CP, Scales SJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA 2009; 106: 4254-9.
17. Queiroz KCS, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP, et al. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 2010; 29: 6314-22.
18. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 2011; 30: 4874-86.
19. Cui D, Xu Q, Wang K, Che X. Gli1 is a potential target for alleviating multidrug resistance of gliomas. J Neurol Sci 2010; 288: 156-66.
20. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190-7.
21. Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008; 7: 2725-35.
22. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 2007; 104: 8455-60.
23. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 2502-11.
24. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361: 1173-8.
25. Tas S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol 2004; 14: 96-102.
26. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361: 1164-72.
27. Jackson-Fisher AJ, McMahon MJ, Lam J, et al. PF-04449913, a small molecule inhibitor of Hedgehog signaling, is effective in inhibiting tumor growth in preclinical models [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; 2011. Abstract nr 4504.
28. Jamieson C, Cortes JE, Oehler V, et al. Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies [abstract]. Blood 2011; 118:s424.
29. Shaik NM, LaBadie RR, Rudin D, Levin WJ. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the Smoothened inhibitor PF-04449913 in healthy volunteers. Cancer Chemother Pharmacol 2014; 742: 411-8.
30. Siu LL, Papadopoulos K, Alberts SR. A first-in-human, phase I study of an oral Hedgehog (Hh) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol 2010; 28: 15s.
31. Rodon Ahnert J, Baselga J, Tawbi HA. A phase I dose-escalation study of LDE225, a Smoothened (SMO)antagonist, inpatients with advanced solid tumors. J Clin Oncol 2010; 28: 15s.